Godavari Biorefineries Ltd (GODAVARIB) is currently trading at 227.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Godavari Biorefineries Limited is an integrated biorefinery and ethanol-based chemical manufacturer operating sugar, distillery, co-generation and specialty bio-chemical plants, producing ethanol, sugar, rectified spirits, ethyl acetate, MPO, 1,3 butylene glycol and other bio-based chemistries from two main manufacturing sites at Sameerwadi and Sakarwadi, serving domestic and export customers across FMCG, chemical and OMC sectors. The bio-based chemicals vertical showed pronounced momentum in Q1 FY27: revenue increased about 19.4% year-on-year to INR168.7 crores and EBITDA rose 53% to INR19.2 crores with margins expanding to 11.4%, driven by debottlenecking and improved product mix; management is allocating INR25 crore for further debottlenecking to capture clear demand from domestic and overseas customers. Consolidated results were mixed: overall revenue was INR557.9 crores, up 4.6% year-on-year, but consolidated profitability was weak with EBITDA of INR2.6 crores and a net loss of INR19.3 crores due to higher inventory carrying costs, elevated feedstock and manufacturing costs, and continued headwinds in the integrated sugar, co-generation and ethanol segment which reported an EBITDA loss. Management highlights strategic optionality: a newly commissioned 200 KLPD grain distillery increases feedstock flexibility and the company is evaluating a 160 KLPD fungible maize/grain front-end to better utilize idle fermentation and distillation capacity, enabling tactical switching between sugar and ethanol depending on market and policy signals. R&D and new product pipelines are material: Godavari obtained a Japanese patent and filed an Indian patent for branched alcohol process, filed CDSCO application for preliminary efficacy trials of a TNBC molecule expected in Q3 FY27, and continues DME pilot trials with final pilot outcomes anticipated by March 2027, demonstrating deliberate diversification into higher-value innovation platforms.

Over the past 52 weeks, Godavari Biorefineries Ltd has traded between a low of ₹194.00 and a high of ₹353.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Godavari Biorefineries Ltd has a market capitalization of approximately 1,092.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Godavari Biorefineries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 4965.23 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,092.35 Cr, Godavari Biorefineries Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Godavari Biorefineries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Godavari Biorefineries Ltd is 4965.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Godavari Biorefineries reported a consolidated net loss of Rs 15.24 crore for the quarter ended September 30, 2026. This was lower than the Rs 41.59 crore loss reported in Q2 FY26.

The results are expected in the July-August 2026 window for the quarter ended June 2026, in line with the broader results season.

They are expected in the July-August 2026 window, as indicated in the preview.

The stock rose after the company announced that the Japan Patent Office granted a patent for its invention, 5-Hydroxy-1,4-naphthalenedione, for use in cancer treatment.